Sucampo Acquires Vtesse Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Sucampo Pharmaceuticals (SCMP) PT Raised to $21 at Maxim Group; Vtesse 'Could Be a Great Deal'
April 3, 2017 3:20 PM EDTMaxim Group raised its price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $21.00 (from $19.00) while maintaining a Buy rating after the company acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $200 million.
Analyst Jason... More
